$heff's $tation of $tocks & $olid DD

[BiotechValues]

$SRNE potential catalyst next week

I don't ever expect much from investor conference participation in terms of short term share price response, but this one may be an exception.

At the JP Morgan Healthcare Conference next week, Dr. Soon-Shiong will be explaining (for the first time) details about Conkwest's Neukoplast technology platform and the exclusive partnership among Sorrento, Conkwest and NantWorks to develop and commercialize "CAR.TNK" (Chimeric Antigen Receptor Tumor-attacking Neukoplast) Cell Lines, the next-generation "off-the-shelf" adoptive cancer immunotherapy.

see pr: http://finance.yahoo.com/news/conkwest-sorrento-nantworks-announce-presentation-140000836.html

To date, there have been no real details re: relationships and JV between Conkwest,(privately held), NantWorks (Dr. Soon-Shiong's privately held company) and Sorrento (SRNE).

I think that will change next week with Dr. Soon-Shiong's presentation. Because the partnership with this trio is a material change for SRNE and it hasn't been fully explained to date, then I expect the company (SRNE)to provide details of the presentation to the public as well.

Track back for article I wrote...